Subject: single-centre, randomised, open-label, single-dose, seven-way cross-over trial single-centre, randomised, open-label, single-dose, seven-way cross-over trial?wash-out days? run-in period? cross-over period? Trial 248.529 was a single-centre, randomised, open-label, single-dose, seven-way cross-over trial ([U05-2046]) to compare the bioavailability of seven prototypes ER formulations (B, C, D, E, F, G and H) to IR tablets. After a run-in period of 7 days (with increasing pramipexole ER:extended-release IR: immediate release HV: healthy volunteers |
You need to be logged in to post in the forum |